GB201706781D0 - Parathyroid hormone fusion polypeptide - Google Patents

Parathyroid hormone fusion polypeptide

Info

Publication number
GB201706781D0
GB201706781D0 GBGB1706781.0A GB201706781A GB201706781D0 GB 201706781 D0 GB201706781 D0 GB 201706781D0 GB 201706781 A GB201706781 A GB 201706781A GB 201706781 D0 GB201706781 D0 GB 201706781D0
Authority
GB
United Kingdom
Prior art keywords
fusion polypeptide
parathyroid hormone
hormone fusion
parathyroid
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1706781.0A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Sheffield
Original Assignee
University of Sheffield
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Sheffield filed Critical University of Sheffield
Priority to GBGB1706781.0A priority Critical patent/GB201706781D0/en
Publication of GB201706781D0 publication Critical patent/GB201706781D0/en
Priority to EP18782783.7A priority patent/EP3609913A2/en
Priority to CA3061088A priority patent/CA3061088A1/en
Priority to US16/608,611 priority patent/US11344606B2/en
Priority to CN201880027437.0A priority patent/CN110546159B/zh
Priority to PCT/GB2018/051120 priority patent/WO2018197895A2/en
Priority to JP2019558571A priority patent/JP2020519250A/ja
Priority to US17/708,394 priority patent/US20220218790A1/en
Priority to JP2022202078A priority patent/JP2023027315A/ja
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1796—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/10—Carbonates; Bicarbonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/635—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Inorganic Chemistry (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
GBGB1706781.0A 2017-04-28 2017-04-28 Parathyroid hormone fusion polypeptide Ceased GB201706781D0 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
GBGB1706781.0A GB201706781D0 (en) 2017-04-28 2017-04-28 Parathyroid hormone fusion polypeptide
EP18782783.7A EP3609913A2 (en) 2017-04-28 2018-04-27 Parathyroid hormone fusion polypeptide
CA3061088A CA3061088A1 (en) 2017-04-28 2018-04-27 Parathyroid hormone fusion polypeptide
US16/608,611 US11344606B2 (en) 2017-04-28 2018-04-27 Parathyroid hormone fusion polypeptide
CN201880027437.0A CN110546159B (zh) 2017-04-28 2018-04-27 甲状旁腺激素融合多肽
PCT/GB2018/051120 WO2018197895A2 (en) 2017-04-28 2018-04-27 Parathyroid hormone fusion polypeptide
JP2019558571A JP2020519250A (ja) 2017-04-28 2018-04-27 副甲状腺ホルモン融合ポリペプチド
US17/708,394 US20220218790A1 (en) 2017-04-28 2022-03-30 Parathyroid hormone fusion polypeptide
JP2022202078A JP2023027315A (ja) 2017-04-28 2022-12-19 副甲状腺ホルモン融合ポリペプチド

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1706781.0A GB201706781D0 (en) 2017-04-28 2017-04-28 Parathyroid hormone fusion polypeptide

Publications (1)

Publication Number Publication Date
GB201706781D0 true GB201706781D0 (en) 2017-06-14

Family

ID=59011076

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1706781.0A Ceased GB201706781D0 (en) 2017-04-28 2017-04-28 Parathyroid hormone fusion polypeptide

Country Status (7)

Country Link
US (2) US11344606B2 (https=)
EP (1) EP3609913A2 (https=)
JP (2) JP2020519250A (https=)
CN (1) CN110546159B (https=)
CA (1) CA3061088A1 (https=)
GB (1) GB201706781D0 (https=)
WO (1) WO2018197895A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201706781D0 (en) * 2017-04-28 2017-06-14 Univ Sheffield Parathyroid hormone fusion polypeptide
SG11202106223RA (en) * 2019-01-11 2021-07-29 Radius Health Inc Methods for detecting neutralizing antibodies to parathyroid hormone (pth) and parathyroid hormone-related peptide (pthrp) analog
CN111876388A (zh) * 2020-07-24 2020-11-03 赛瑞诚(苏州)生物科技有限公司 一种骨和骨组织靶向外泌体及其制备方法和应用
CN118126197B (zh) * 2024-03-19 2025-02-25 康众(广东)生物医药有限公司 一种重组pth融合蛋白及其构建方法与应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6770623B1 (en) 1997-12-09 2004-08-03 Eli Lilly And Company Stabilized teriparatide solutions
JPH11285388A (ja) 1998-04-03 1999-10-19 Jcr Pharmaceuticals Co Ltd キメラレセプター発現細胞とその用途
AU2001257169C1 (en) 2000-04-21 2011-06-16 Tufts Medical Center, Inc. G-protein coupled receptor (GPCR) agonists and antagonists and methods of activating and inhibiting GPCR using the same
EP1771467A2 (en) 2004-07-26 2007-04-11 Asterion Limited Linkers
KR100700869B1 (ko) 2005-06-03 2007-03-29 재단법인 목암생명공학연구소 Ｐｔｈ, 완충제 및 안정제를 포함하는 안정한 ｐｔｈ조성물
WO2008124166A2 (en) 2007-04-09 2008-10-16 The Board Of Trustees Of The University Of Arkansas Fusion proteins of collagen-binding domain and parathyroid hormone
GB0717985D0 (en) 2007-07-20 2007-10-24 Asterion Ltd Growth hormone fusion proteins
EP2411038B1 (en) 2009-03-27 2016-12-28 Van Andel Research Institute Parathyroid hormone peptides and parathyroid hormone-related protein peptides and methods of use
CN105153313A (zh) 2010-02-16 2015-12-16 诺沃—诺迪斯克有限公司 因子viii融合蛋白
WO2011143406A2 (en) 2010-05-13 2011-11-17 The General Hospital Corporation Parathyroid hormone analogs and uses thereof
GB201104285D0 (en) * 2011-03-15 2011-04-27 Asterion Ltd Modified receptor fusion proteins
WO2013120060A1 (en) 2012-02-09 2013-08-15 The Board Of Trustees Of The University Of Arkansas Delivery of therapeutic agents by a collagen binding protein
ES2695161T3 (es) 2011-12-14 2019-01-02 Univ Arkansas Administración de agentes terapéuticos mediante una proteína de unión a colágeno
WO2013108235A1 (en) 2012-01-20 2013-07-25 Lupin Limited Stabilized pth formulation
CA2919477A1 (en) * 2013-07-31 2015-02-05 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating thermogenesis using pth-related and egf-related molecules
JP6805174B2 (ja) 2015-05-12 2020-12-23 アメリカ合衆国 神経成長因子シグナルペプチド及び副甲状腺ホルモンを含むａａｖ分離株及び融合タンパク質
GB201706781D0 (en) * 2017-04-28 2017-06-14 Univ Sheffield Parathyroid hormone fusion polypeptide

Also Published As

Publication number Publication date
US20220218790A1 (en) 2022-07-14
JP2023027315A (ja) 2023-03-01
WO2018197895A3 (en) 2019-01-17
CN110546159B (zh) 2023-08-22
WO2018197895A2 (en) 2018-11-01
US20200164033A1 (en) 2020-05-28
CN110546159A (zh) 2019-12-06
JP2020519250A (ja) 2020-07-02
US11344606B2 (en) 2022-05-31
CA3061088A1 (en) 2018-11-01
EP3609913A2 (en) 2020-02-19

Similar Documents

Publication Publication Date Title
GB201719557D0 (en) Polypeptide
ZA201705961B (en) Anti-cancer fusion polypeptide
IL254965A0 (en) fusion proteins
ZA201706061B (en) Anti-cancer fusion polypeptide
SG11202101904UA (en) Spd-1 variant - fc fusion proteins
ZA202003845B (en) Fusion proteins
IL271268A (en) A fusion protein that extends half-life
ZA201904705B (en) Recombinant bcg overexpressing phop-phor
SG11202000775SA (en) Fusion tags for recombinant protein expression
ZA202102533B (en) Fusion protein
GB201706781D0 (en) Parathyroid hormone fusion polypeptide
GB201707139D0 (en) Polypeptides
IL269477A (en) Polypeptides that bind to IL-1R-1
GB201810052D0 (en) Polypeptide
GB201913804D0 (en) Fusion polypeptides
GB201712792D0 (en) Fusion protein
GB201708277D0 (en) A Recombinant protein
GB201602850D0 (en) Fusion proteins
GB201719520D0 (en) Neuroprotectvie peptide
GB201806655D0 (en) Polypeptide
GB201617799D0 (en) Fusion polypeptide
GB201708471D0 (en) Polypeptide
GB201503789D0 (en) Fusion polypeptide
PT3298030T (pt) Polipeptídeo de fusão anticancro
GB201711620D0 (en) Peptides

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)